Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03102918 · ClinicalTrials.gov registry record · Phase 1
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
A Phase 1 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03102918 is a Phase 1 study that has completed, run by Mclean Hospital. The registered enrollment target is 10 participants.
The verdict
NCT03102918, a Phase 1 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use compared to placebo as measured by the 2 primary outcome measures: 1) quantitative THC levels and 2) self-report by Timeline Follow Back. Secondary outcome measures will include treatment retention, patient satisfaction, cannabis withdrawal, cannabis craving, depressive symptoms, anxiety symptoms, , compliance, and cigarette use.
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-02-20 |
| Est. Completion | 2017-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03102918
The ClinicalTrials.gov registry entry for NCT03102918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03102918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03102918 about?
NCT03102918 is a clinical study titled "Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder". Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use compared to placebo as measured by the 2 primary outcome measures: 1) quan...
What is the current status of trial NCT03102918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-02-20. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03102918?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT03102918?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.